<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">826</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"/><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>CLINICAL STUDY OF MUTLAZIMA QABL HAIZ (PREMENSTRUAL SYNDROME) AND ITS MANAGEMENT WITH UNANI FORMULATION - A RANDOMIZED CONTROLLED TRIAL&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>afeeza</surname><given-names>H</given-names></name></contrib><contrib contrib-type="author"><name><surname>Naveed</surname><given-names>Wasia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shameem</surname><given-names>Ismath</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tabassum</surname><given-names>K.</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>12</day><month>07</month><year>2014</year></pub-date><volume>)</volume><issue/><fpage>51</fpage><lpage>57</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Background and Objectives: Mutlazima Qabl Haiz (Premenstrual Syndrome) is a group of menstruation related cyclical disorder manifested by emotional and physical symptoms in the second half of the menstrual cycle, which subsides after the beginning of menstruation. During the reproductive years, 80-90% of menstruating women experience symptoms like breast pain, bloating, acne, constipation, mood swings, irritability and depression that fore warns them of impending menstruation. The objective of the study was to evaluate the efficacy of Tukhme Sambhalu (Vitexagnuscastus) and Arq Pudina (Menthapiperita) in the management of Mutlazima Qabl Haiz. Methods: A single blind, randomized placebo controlled study was carried out in Gynaec OPD of the Institute?s Hospital, Bangalore. Patients were randomly allocated to test (n=30) and control (n=30) groups. Patients in the age group of 13-40 years with regular menstrual cycle were included in the study irrespective of marital status and parity. In test group, Tukhme Sambhalu1 gm and Arq Pudina 36 ml were administered orally twice daily, 10 days prior to menstruation in every cycle for 3 consecutive months. In control group placebo was given for the same duration. Severity of Premenstrual Syndrome was assessed by Premenstrual Tension Syndrome Scale and reduction in the Premenstrual Tension Syndrome Scale score was noted in each cycle. The data were analyzed using Analysis of variance - one way with Turkey Kramer Multiple pair comparison test and Premenstrual Tension Syndrome Scale scores of the two groups were compared by Chi Square test. Results: In test group, 70% patients were cured while 16.66% and 10% were relieved and partially relieved respectively, while 3.33% patients showed no response. In control group, the cured, relieved, and partially relieved patients were 23.33%, 23.33% and 20% respectively where as 33.33% patients showed no response. Significant reduction in the Premenstrual Tension Syndrome Scale scores was observed in test group than compared to control group (p__ampersandsignlt;0.01). Interpretation and Conclusion: The test drugs, Tukhme Sambhaluand Arq Pudina were effective in reducing the somatic and psychological symptoms of Mutlazima Qabl Haizas compared to placebo.vvv&#13;
</p></abstract><kwd-group><kwd>Premenstrual Syndrome; Premenstrual Tension Syndrome Scale; Vitexagnuscastus; Menthapiperita.</kwd></kwd-group></article-meta></front></article>
